DexCom, Inc. to Post Q1 2022 Earnings of $0.55 Per Share, SVB Leerink Forecasts (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCMGet Rating) – Stock analysts at SVB Leerink decreased their Q1 2022 earnings estimates for DexCom in a research report issued to clients and investors on Monday, April 18th. SVB Leerink analyst D. Antalffy now anticipates that the medical device company will post earnings per share of $0.55 for the quarter, down from their previous estimate of $0.63. SVB Leerink also issued estimates for DexCom’s FY2022 earnings at $3.11 EPS, FY2023 earnings at $3.90 EPS, FY2024 earnings at $5.09 EPS and FY2025 earnings at $5.98 EPS.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, February 10th. The medical device company reported $0.68 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.18). DexCom had a net margin of 6.32% and a return on equity of 12.87%. The company had revenue of $698.20 million during the quarter, compared to analysts’ expectations of $698.66 million. During the same period in the previous year, the business earned $0.91 earnings per share. The business’s revenue for the quarter was up 22.7% compared to the same quarter last year.

Several other equities analysts also recently weighed in on the stock. Guggenheim upgraded shares of DexCom from a “neutral” rating to a “buy” rating and set a $580.00 price target on the stock in a report on Friday, January 7th. Morgan Stanley cut their price target on shares of DexCom from $570.00 to $514.00 and set an “equal weight” rating on the stock in a report on Friday, February 11th. Wells Fargo & Company upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and set a $575.00 price target on the stock in a report on Wednesday, January 19th. Robert W. Baird dropped their price objective on shares of DexCom from $625.00 to $560.00 in a research note on Friday, February 11th. Finally, StockNews.com started coverage on shares of DexCom in a research note on Thursday, March 31st. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Buy” and a consensus price target of $574.29.

Shares of NASDAQ:DXCM opened at $491.79 on Wednesday. DexCom has a twelve month low of $318.45 and a twelve month high of $659.45. The company’s 50 day moving average is $450.38 and its 200 day moving average is $506.06. The company has a current ratio of 5.11, a quick ratio of 4.62 and a debt-to-equity ratio of 0.76. The company has a market cap of $48.26 billion, a PE ratio of 317.29, a price-to-earnings-growth ratio of 8.26 and a beta of 0.94.

DexCom shares are going to split before the market opens on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly created shares will be distributed to shareholders after the closing bell on Thursday, June 9th.

A number of hedge funds have recently made changes to their positions in DXCM. Commonwealth Equity Services LLC raised its holdings in shares of DexCom by 39.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 12,068 shares of the medical device company’s stock worth $6,599,000 after acquiring an additional 3,427 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of DexCom by 5.6% during the 3rd quarter. Janney Montgomery Scott LLC now owns 7,261 shares of the medical device company’s stock worth $3,971,000 after acquiring an additional 382 shares during the period. Whittier Trust Co. raised its holdings in shares of DexCom by 32.6% during the 3rd quarter. Whittier Trust Co. now owns 423 shares of the medical device company’s stock worth $231,000 after acquiring an additional 104 shares during the period. Nordea Investment Management AB raised its holdings in shares of DexCom by 109.7% during the 3rd quarter. Nordea Investment Management AB now owns 121,478 shares of the medical device company’s stock worth $66,772,000 after acquiring an additional 63,542 shares during the period. Finally, LaFleur & Godfrey LLC purchased a new position in shares of DexCom during the 3rd quarter worth $206,000. Institutional investors own 95.14% of the company’s stock.

In other DexCom news, insider Steven Robert Pacelli sold 250 shares of the firm’s stock in a transaction on Wednesday, February 23rd. The stock was sold at an average price of $394.33, for a total value of $98,582.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 3,000 shares of the firm’s stock in a transaction on Monday, February 14th. The shares were sold at an average price of $418.04, for a total value of $1,254,120.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,898 shares of company stock worth $4,829,689 in the last quarter. Insiders own 0.52% of the company’s stock.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.